Corcept Therapeutics Incorporated filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 3, 2026, reporting third-quarter net product revenue of $340,472 thousand and net income of $126,778 thousand.
Key Highlights
- Q3 2026 net product revenue: $340,472 thousand, up from $207,638 thousand in Q3 2025.
- Q3 2026 net income: $126,778 thousand, compared to $19,668 thousand in the same quarter of 2025.
- Nine-month net product revenue: $761,522 thousand for the nine months ended September 30, 2026, versus $559,282 thousand for the same period in 2025.
- Diluted net income per common share: $1.01 for Q3 2026, compared to $0.16 for Q3 2025.
- Total assets: $1,034,027 thousand as of September 30, 2026, up from $836,651 thousand at December 31, 2025.
- Shares outstanding: 109,443,109 shares of common stock as of October 22, 2026.
- Operating cash flow: $159,662 thousand for the nine months ended September 30, 2026.
Corcept Therapeutics Q3 2026 Financial Results: Revenue and Income Detail
According to the filing, Corcept Therapeutics Incorporated (NASDAQ:CORT) reported net product revenue of $340,472 thousand for the three months ended September 30, 2026, compared to $207,638 thousand for the three months ended September 30, 2025. For the nine months ended September 30, 2026, net product revenue totaled $761,522 thousand, versus $559,282 thousand for the comparable prior-year period. Total operating expenses for Q3 2026 were $225,748 thousand, leaving income from operations of $114,724 thousand, against $10,219 thousand in Q3 2025.
The company disclosed net income of $126,778 thousand for the third quarter of 2026, which included an income tax benefit of $6,471 thousand. Basic net income per common share was $1.17 and diluted net income per common share was $1.01 for Q3 2026, based on weighted-average diluted shares outstanding of 123,201 thousand. For the nine months ended September 30, 2026, net income totaled $138,004 thousand, with diluted net income per common share of $1.13.
The condensed consolidated balance sheet as of September 30, 2026, reflected total assets of $1,034,027 thousand, compared to $836,651 thousand at December 31, 2025. Total stockholders' equity stood at $833,740 thousand at the end of the quarter. The filing reported net cash provided by operating activities of $159,662 thousand for the nine months ended September 30, 2026. Stock-based compensation for the same nine-month period was $81,902 thousand. The company repurchased common stock totaling $5,745 thousand under its Stock Repurchase Program during the nine months ended September 30, 2026, compared to $172,915 thousand in the prior-year period.
What Was Disclosed
Corcept Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing unaudited financial statements including income, balance sheet, and cash flow data, along with management's discussion and risk factors.



Please wait processing your request...